Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 26;97(17):e1737-e1742.
doi: 10.1212/WNL.0000000000012724. Epub 2021 Sep 7.

Association of Elbow Flexor MRI Fat Fraction With Loss of Hand-to-Mouth Movement in Patients With Duchenne Muscular Dystrophy

Affiliations

Association of Elbow Flexor MRI Fat Fraction With Loss of Hand-to-Mouth Movement in Patients With Duchenne Muscular Dystrophy

Karin J Naarding et al. Neurology. .

Abstract

Background and objectives: To study the potential of quantitative MRI (qMRI) fat fraction (FF) as a biomarker in nonambulant patients with Duchenne muscular dystrophy (DMD), we assessed the additive predictive value of elbow flexor FF to age at loss of hand-to-mouth movement.

Methods: Nonambulant patients with DMD (age ≥8 years) were included. Four-point Dixon MRI scans of the right upper arm were performed at baseline and at the 12-, 18-, or 24-month follow-up. Elbow flexor FFs were determined from 5 central slices. Loss of hand-to-mouth movement was determined at study visits and by phone calls every 4 months. FFs were fitted to a sigmoidal curve by use of a mixed model with random slope to predict individual trajectories. The added predictive value of elbow flexor FF to age at loss of hand-to-mouth movement was calculated from a Cox model with the predicted FF as a time-varying covariate, yielding a hazard ratio.

Results: Forty-eight MRIs of 20 patients with DMD were included. The hazard ratio of a percent-point increase in elbow flexor FF for the time to loss of hand-to-mouth movement was 1.12 (95% confidence interval 1.04-1.21; p = 0.002). This corresponded to a 3.13-fold increase in the instantaneous risk of loss of hand-to-mouth movement in patients with a 10-percent points higher elbow flexor FF at any age.

Discussion: In this prospective study, elbow flexor FF predicted loss of hand-to-mouth movement independently of age. qMRI-measured elbow flexor FF can be used as a surrogate endpoint or stratification tool for clinical trials in nonambulant patients with DMD.

Classification of evidence: This study provides Class II evidence that qMRI FF of elbow flexor muscles in patients with DMD predicts loss of hand-to-mouth movement independently of age.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Longitudinal Clinical and FFEF Data
(A) Example of a region of interest drawn on the elbow flexor muscles (line) is shown on a water image (left) and corresponding fat image (right). (B) Longitudinal performance of the upper limb (PUL) 2.0 total scores (maximum 42 points) are plotted vs age. PUL total scores decrease with age, but there is a large variation in scores between patients with Duchenne muscular dystrophy of similar ages. (C) Elbow flexor fat fraction (FFEF) results that were acquired are plotted vs age, as well as FFEF results that were predicted with a logit transformation, linear (mixed) model, and logistic transformation. Patients with higher FFEF results at younger ages or faster FFEF increases had steeper predicted FFEF slopes. (D) Predicted FFEF results are plotted vs age, and predicted FFEF at age at loss of hand-to-mouth movement is shown with a cross. Colors used in panels B–D are unique for each participant.
Figure 2
Figure 2. Elbow Flexor Fat Fraction and Preserved Hand-to-Mouth Movement vs Age
In (A) we generated an FFEF growth chart with a 3rd, 10th, 25th, 50th, 75th, 90th and 97th percentile curve from the predicted FFEF data. (B) Using the resulting hazard ratio, we transformed the predicted FFEF growth curves to a 3rd, 10th, 25th, 50th, 75th, 90th and 97th percentile survival curve for preserved hand-to-mouth movement. A patient on the 3rd percentile in the FFEF growth chart is also on the 3rd percentile in the survival chart.

References

    1. McDonald CM, Henricson EK, Abresch RT, et al. . Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451-461. - PubMed
    1. European Medicines Agency (EMA). CHMP guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy. Accessed December 18, 2020. Available at: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/....
    1. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373-386. - PubMed
    1. Naarding KJ, Reyngoudt H, van Zwet EW, et al. . MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. Neurology. 2020;94(13):e1386-e1394. - PMC - PubMed
    1. Rooney WD, Berlow YA, Triplett WT, et al. . Modeling disease trajectory in Duchenne muscular dystrophy. Neurology. 2020;94(15):e1622-e1633. - PMC - PubMed

Publication types